The HER2‐targeted therapies, including trastuzumab, pertuzumab, lapatinib, and ado‐trastuzumab emtansine, have been developed and investigated during the past two decades, which definitely improved the treatment efficacy in patients with HER2‐positive breast cancer.9, 10, 11, 12. The gene discussed is ERBB2; the disease is breast carcinoma.